Early Phase 1 Gastro-oesophageal Reflux Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with GERD (gastroesophageal reflux disease, also known as chronic acid reflux)
- People who are in generally stable health with no current serious complications
- People who are currently taking a stable, regular dose of a acid-reducing medication called rabeprazole (a type of proton pump inhibitor, or PPI)
Who may not be able to join:
- People who have used probiotic or prebiotic supplements or products in the past 4 weeks
- People who are currently pregnant or breastfeeding
- People who have taken antibiotic or other antimicrobial medications in the past 4 weeks
- People who have had a respiratory (lung or airway) or gastrointestinal (stomach or bowel) infection in the past 2 weeks
- People who have a serious ongoing health condition that could affect the study results, such as cancer, diabetes, inflammatory bowel disease, or a condition called SIBO (small intestinal bacterial overgrowth)
- People who have previously had certain surgeries, particularly a fundoplication (a surgery for reflux) or removal of part of the oesophagus or stomach
- People who have a diagnosed psychiatric condition or a condition affecting memory or thinking
- People who have a known allergy or sensitivity to any ingredient in the treatment being tested in this trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +420588445308
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change of % of patients with dysbiosis in the gastrointestinal tract caused by the disease itself and/or pharmacotherapy - as assessed by using whole-genome sequencing
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.